Survivin 重组兔单克隆抗体 (S-2334-26)-S0B6183

Survivin is a 16.5 kDa member of the inhibitor of apoptosis (IAP) family that uniquely integrates control of cell division and suppression of apoptosis by binding to caspases-3 and -7, thereby blocking the terminal execution phase of programmed cell death, while also associating with the chromosomal passenger complex at centromeres during mitosis to ensure accurate chromosome segregation; it is transcriptionally repressed by wild-type p53, strongly up-regulated in virtually every human cancer through PI3K/AKT, STAT3, β-catenin/TCF and HIF-1α pathways, and correlates with poor prognosis, resistance to chemo- and radiotherapy, and increased tumor recurrence, making it a high-value therapeutic target addressed by antisense oligonucleotides, dominant-negative mutants, small-molecule antagonists and immunotherapies that collectively seek to restore apoptotic sensitivity and inhibit unchecked proliferation in malignant cells.